 |
||||||||||
 |
 |
|||||||||
 |
 |
 |
 |
 |
||||||
 |
 |
|||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
Kenneth A. Thomas, Ph.D. | |||||||||
 Vice President, Research and Development Dr. Thomas brings to CVBT over two decades of experience at the Merck Research Laboratories in scientific research and pharmaceutical development of therapeutic proteins and small molecule enzyme inhibitors. His scientific and managerial expertise includes the areas of biological chemistry, molecular biology, cell biology and animal pharmacology spanning cardiology, endocrinology, dermatology, ophthalmology and oncology. He has served on The Journal of Biological Chemistry editorial board, co-organized national and international meetings on growth factors, angiogenesis, protein kinases and signal transduction, and has over 90 publications and 40 issued patents. While at Merck, Dr. Thomas initiated, built and directed the preclinical biology programs leading to six angiogenic and anti-angiogenic development candidates. This work was based on his initial discovery and characterization of FGF-1 and research on functionally related angiogenic growth factors and their receptors. Dr. Thomas received a B.S. degree in Chemistry from the University of Delaware and a Ph.D. in Biochemistry from Duke University followed by postdoctoral fellowships at the National Institutes of Health and Washington University in St. Louis. < Back to Officers & Key Personnel
Use of
this site constitutes agreement to our Terms and Conditions | ||||||||||
 |
||||||||||
 |
|
|
|
|
|
|
|
|
|
|